Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kissei Out-Licenses Parkinson’s Med to Hong Kong’s Affamed
October 12, 2020
- Canagliflozin Approved in Indonesia: Mitsubishi Tanabe
October 12, 2020
- Takeda-Led Alliance Kicks Off Global PIII for COVID-19 Plasma Therapy
October 12, 2020
- Takeda, US Arrowhead Join Forces on Intractable Liver Disease Therapy
October 12, 2020
- Sumitomo Chemical, Sumitomo Dainippon Launch JV for Cell Therapy CDMO
October 12, 2020
- Maruho Taps Meiji as Copromotion Partner for Amenalief
October 9, 2020
- Towa Plans to Start Full-Scale Continuous Manufacturing in FY2024, Aiming at Whole Automated Process
October 9, 2020
- University of Tokyo, Eisai Link Arms for Research on Targeted Protein Degradation Technology
October 9, 2020
- AnGes Out-Licenses Collategene to Turkish Pharma
October 9, 2020
- Sumitomo Dainippon Rejigs Organization to Become Top CNS Player in Japan, Sets 50 Billion Yen Near-Term Goal
October 8, 2020
- Japan Ethical Drug Sales Dip 9.0% in August: Crecon
October 8, 2020
- Pfizer, Merck Biopharma to End Xalkori Copromotion in Japan
October 8, 2020
- Fujifilm to Expand Viral Vector CDMO Biz to Europe
October 8, 2020
- Hisamitsu Initiates Japan PIII of Palmar Hyperhidrosis Drug, Aims at Filing in FY2022
October 8, 2020
- 1 More Soft Bag Product Recalled Over Flawed Testing at Kyowa CritiCare
October 8, 2020
- HUYA Files Novel T-Cell Leukemia-Lymphoma Med in Japan
October 8, 2020
- Pfizer Renames Japan Subsidiaries as Mylan Deal Set to Close Soon; Upjohn Biz Now Separate
October 7, 2020
- Keytruda Top Selling Drug in September: Encise
October 7, 2020
- Eisai, 4 Research Organizations Begin Collaborative Project for COVID-19 Treatments
October 7, 2020
- Sunovion’s Apomorphine Sublingual Hits US Market
October 7, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…